Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD)
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
Background: This European multicenter study aimed to elucidate suicidality in major depressive disorder. Previous surveys suggest a prevalence of suicidality in major depressive disorder of ≥50%, but little is known about the association of different degrees of suicidality with socio-demographic, psychosocial, and clinical characteristics. Methods: We stratified 1410 major depressive disorder patients into 3 categories of suicidality based on the Hamilton Rating Scale for Depression item 3 (suicidality) ratings (0=no suicidality; 1-2=mild/moderate suicidality; 3-4=severe suicidality). Chi-squared tests, analyses of covariance, and Spearman correlation analyses were applied for the data analyses. Results: The prevalence rate of suicidality in major depressive disorder amounted to 46.67% (Hamilton Rating Scale for Depression item 3 score ≥1). 53.33% were allocated into the no, 38.44% into the mild/moderate, and 8.23% into the severe suicidality patient group. Due to the stratification of our major depressive disorder patient sample according to different levels of suicidality, we identified some socio-demographic, psychosocial, and clinical variables differentiating from the patient group without suicidality already in presence of mild/moderate suicidality (depressive symptom severity, treatment resistance, psychotic features, add-on medications in general), whereas others separated only when severe suicidality was manifest (inpatient treatment, augmentation with antipsychotics and benzodiazepines, melancholic features, somatic comorbidities). Conclusions: As even mild/moderate suicidality is associated with a failure of achieving treatment response, adequate recognition of this condition should be ensured in the clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Patients with TRD have higher rates of relapse and higher suicide rates, compared to patients with MDD who are not treatment resistant [3, 4].”
From Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study (2023) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Self-citation(1998) · PubMed · Cited by 10,216
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 2×
“However, the criticism of the FDA on the HAM-D item 3 assessment should be considered in this regard, as it led subsequently to the development of a further rating instrument for the appraisal of suicidal ideation and behavior in clinical and research settings, the Columbia–Suicide Severity Rating Scale (Posner et al.…”
BackgroundThe size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754 · cited 2×
“Major depressive disorder (MDD) represents one of the most common medical illnesses worldwide with a median 12-month prevalence rate of 6.9% (Wittchen et al., 2011) and a lifetime prevalence rate varying between 11.2% and 16% (Bauer et al., 2013; Dold and Kasper, 2017).”
BackgroundInfluentialPrevalence of and Risk Factors for Lifetime Suicide Attempts in the National Comorbidity Survey
Kessler, R. C., Borges, G., & Walters, E. E. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.7.617 · Cited by 2,514
Risk factors for suicide in psychiatric outpatients: A 20-year prospective study.
Brown, G. K., Beck, A. T., Steer, R. A., & Grisham, J. R. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.3.371 · Cited by 1,317
Excess Mortality in Bipolar and Unipolar Disorder in Sweden
Ösby, U., Brandt, L., Correia, N., Ekbom, A., & Sparén, P. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.9.844 · Cited by 1,120 · cited 1×
“It is estimated that up to 10% of all MDD patients attempt suicide (Holma et al., 2014), and population-based surveys suggest for inpatients with MDD a 20-fold increased risk of completed suicide compared with the general population (Høyer et al., 2000; Osby et al., 2001).”
BackgroundBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Self-citationBauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632 · cited 2×
“Major depressive disorder (MDD) represents one of the most common medical illnesses worldwide with a median 12-month prevalence rate of 6.9% (Wittchen et al., 2011) and a lifetime prevalence rate varying between 11.2% and 16% (Bauer et al., 2013; Dold and Kasper, 2017).”
BackgroundInfluentialFergusson, D., Doucette, S., Glass, K. C., Shapiro, S., Healy, D., Hebert, P., & Hutton, B. (2005) · BMJ · doi:10.1136/bmj.330.7488.396 · Cited by 510
Gunnell, D., Saperia, J., & Ashby, D. (2005) · BMJ · doi:10.1136/bmj.330.7488.385 · Cited by 387
Suicidal Ideation and Attempts Among Psychiatric Patients With Major Depressive Disorder
Sokero, T. P., Melartin, T. K., Rytsälä, H. J., Leskelä, U. S., Lestelä-Mielonen, P. S., & Isometsä, E. T. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0916 · Cited by 375
Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.
Beasley, C. M., Dornseif, B. E., Bosomworth, J. C., Sayler, M. E., Rampey, A. H., Heiligenstein, J. H., Thompson, V. L., Murphy, D. J., & Masica, D. N. (1991) · BMJ · doi:10.1136/bmj.303.6804.685 · Cited by 361
Barbui, C., Esposito, E., & Cipriani, A. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.081514 · Cited by 275
Xu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., Glue, P., Lapidus, K., McGirr, A., Somogyi, A. A., et al. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv124 · Cited by 226
Is it valid to measure suicidal ideation by depression rating scales?
Desseilles, M., Perroud, N., Guillaume, S., Jaussent, I., Genty, C., Malafosse, A., & Courtet, P. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.11.013 · Cited by 208
Holma, K. M., Haukka, J., Suominen, K., Valtonen, H. M., Mantere, O., Melartin, T. K., Sokero, T. P., Oquendo, M. A., & Isometsä, E. T. (2014) · Bipolar Disorders · doi:10.1111/bdi.12195 · Cited by 175 · cited 1×
“It is estimated that up to 10% of all MDD patients attempt suicide (Holma et al., 2014), and population-based surveys suggest for inpatients with MDD a 20-fold increased risk of completed suicide compared with the general population (Høyer et al., 2000; Osby et al., 2001).”
BackgroundThe Risk of Suicide With Selective Serotonin Reuptake Inhibitors in the Elderly
Juurlink, D. N., Mamdani, M. M., Kopp, A., & Redelmeier, D. A. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.5.813 · Cited by 174
Høyer, E. H., Mortensen, P. B., & Olesen, A. V. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.1.76 · Cited by 129
Suicidal behaviors in adult psychiatric outpatients, I: Description and prevalence
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.1.108 · Cited by 123
Evidence-based pharmacotherapy of treatment-resistant unipolar depression
Dold, M., & Kasper, S. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2016.1248852 · Cited by 118
Self-citationMontgomery, S., Dünner, D. L., & Dunbar, G. C. (1995) · European Neuropsychopharmacology · doi:10.1016/0924-977x(94)00131-t · Cited by 116
Self-citationAdministration of ketamine for unipolar and bipolar depression
Kraus, C., Rabl, U., Vanicek, T., Carlberg, L., Popovic, A., Spies, M., Bartova, L., Gryglewski, G., Papageorgiou, K., Lanzenberger, R., et al. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2016.1254802 · Cited by 110
Self-citationMöller, H., Baldwin, D. S., Goodwin, G. M., Kasper, S. F., Okasha, A., Stein, D. J., Tandon, R., Versiani, M., & Pharmacopsychiatry, T. W. S. O. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-008-3002-1 · Cited by 103
Self-citationDeterminants of Suicidal Ideation: The Role of Substance Use Disorders
Pages, K. P., Russo, J. E., Roy-Byrne, P. P., Ries, R. K., & Cowley, D. S. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1109 · Cited by 103
Zisook, S., Trivedi, M., Warden, D., Lebowitz, B., Thase, M., Stewart, J., Moutier, C., Fava, M., Wisniewski, S., Luther, J., et al. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.002 · Cited by 103
Method of assessment determines prevalence of suicidal ideation among patients with depression
Vuorilehto, M., Valtonen, H. M., Melartin, T., Sokero, P., Suominen, K., & Isometsä, E. T. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2013.08.005 · Cited by 81
Suicidal Ideation in Major Depression: Sex Differences and Impact of Comorbid Anxiety
Schaffer, A., Levitt, A. J., Bagby, R. M., Kennedy, S. H., Levitan, R. D., & Joffe, R. T. (2000) · The Canadian Journal of Psychiatry · doi:10.1177/070674370004500906 · Cited by 67
Seemüller, F., Riedel, M., Obermeier, M., Bauer, M., Adli, M., Mundt, C., Holsboer, F., Brieger, P., Laux, G., Bender, W., et al. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009139 · Cited by 64
Acharya, N., Rosen, A. S., Polzer, J. P., D'Souza, D. N., Perahia, D. G., Cavazzoni, P. A., & Baldessarini, R. J. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000246216.26400.db · Cited by 64
Möller, H. (2006) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-006-0650-x · Cited by 62
Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Brutsche, N. E., Furey, M. L., & Zarate, C. A. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu039 · Cited by 56
Zisook, S., Lesser, I. M., Lebowitz, B., Rush, A. J., Kallenberg, G., Wisniewski, S. R., Nierenberg, A. A., Fava, M., Luther, J. F., Morris, D. W., et al. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06724 · Cited by 55 · cited 1×
“However, most of these surveys assessed suicidality before implementing adequate antidepressant treatment (Zisook et al., 2009, 2011; Morris et al., 2010), whereas our patient sample already received a course of antidepressants before the cross-sectional data collection process and subsequently…”
BackgroundKasper, S. F., Zivkov, M., Roes, K. C. B., & Pols, A. G. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00394-x · Cited by 38
Self-citationKasper, S., Montgomery, S. A., Möller, H.-J., van Oers, H. J., Jan Schutte, A., Vrijland, P., & van der Meulen, E. A. (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970701691503 · Cited by 34
Self-citationTermorshuizen, F., Palmen, S. J. M. C., & Heerdink, E. R. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv081 · Cited by 25
Suicidal risk during controlled clinical investigations of fluvoxamine.
Letizia, C., Kapik, B. M., & Flanders, W. D. (1996) · PubMed · Cited by 24
Indicators of pretreatment suicidal ideation in adults with major depressive disorder
Morris, D. W., Trivedi, M. H., Husain, M. M., D, M. F. M., Budhwar, N., Wisniewski, S. R., Miyahara, S., Gollan, J. K., Davis, L. L., Daly, E. J., et al. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01516.x · Cited by 20
Baldessarini, R. J., Lau, W. K., Sim, J. Z. T., Sum, M. Y., & Sim, K. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw092 · Cited by 20
Cited by
Ionescu, D. F., Fu, D.-J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa068 · Cited by 418
Self-citationMcAllister-Williams, R. H., Arango, C., Blier, P., Demyttenaere, K., Falkai, P., Gorwood, P., Hopwood, M., Javed, A., Kasper, S., Malhi, G. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.02.023 · Cited by 278
Self-citationCai, H. X., Jin, Y., Liu, S., Zhang, Q., Zhang, L., Cheung, T. C. C., Balbuena, L., & Xiang, Y. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.05.115 · Cited by 169
Bartova, L., Dold, M., Kautzky, A., Fabbri, C., Spies, M., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., et al. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1635270 · Cited by 152
“Therefore, clinicians may tend to prefer SGAs in routine clinical care (Dold et al. 2018b).”
BackgroundMethodResultInfluentialSelf-citationZaki, N., Chen, L., Lane, R., Doherty, T., Drevets, W. C., Morrison, R. L., Sanacora, G., Wilkinson, S. T., Popova, V., & Fu, D.-J. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01577-5 · Cited by 137
Metadata
- Authors
- Dold, M., Bartova, L., Fugger, G., Kautzky, A., Souery, D., Mendlewicz, J., Papadimitriou, G. N., Dikeos, D., Ferentinos, P., Porcelli, S., Serretti, A., Zohar, J., Montgomery, S., & Kasper, S.
- Affiliations
- Medical University of Vienna (AT)
- Université Libre de Bruxelles (BE)
- National and Kapodistrian University of Athens (GR)
- University of Bologna (IT)
- Tel Aviv University (IL)
- University of London (GB)
- Corresponding author
- Kasper, Siegfried
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-02-23
- Volume
- 21
- Issue
- 6
- Pages
- 539-549
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC6007240
- OpenAlex
- W2790805260
- Cited by
- 82
- References
- 42
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 14 · 2023: 13 · 2022: 9 · 2021: 16 · 2020: 10 · 2019: 4 · 2018: 1
- FWCI
- 9.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Funders
- H. Lundbeck A/S
- Topics
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- major depressive disorder, suicidality, treatment-resistant depression, depression severity, psychotic features, endogenous depression, somatic comorbidity, antipsychotic augmentation, inpatient care
- MeSH terms
- Antidepressive Agents, Cross-Sectional Studies, Major Depressive Disorder, Europe, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Retrospective Studies, Socioeconomic Factors, Suicide, Comorbidity, Prevalence, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

